【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於有骨折風險之老年人。

Sertraline is used in the treatment of major depressive disorder
#仿單變更2021#仿單變更2022

Sertraline, a selective serotonin-reuptake inhibitor (SSRI), is an antidepressant agent.

Sertraline appears to be slowly but well absorbed from the GI tract following oral administration. It is approximately 98% bound to plasma proteins, principally to albumin and α1-acid glycoprotein. Following oral administration, sertraline and its metabolites are excreted in both urine and feces. The elimination half-life of sertraline averages approximately 25–26 hours and that of desmethylsertraline averages about 62–104 hours.

Hypersensitivity to the active substance or any of the excipients. Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia.

Sertraline and its principal metabolite, N-desmethylsertraline, are distributed into milk. Sertraline should be used with caution in nursing women, and women should be advised to notify their physician if they plan to breast-feed.

Significant: Activation of mania or hypomania, Bleeding risk, Fragility fractures, Hyponatremia, Ocular effects(acute angle-closure glaucoma,increased risk of cataract development), Serotonin syndrome, Suicidal thinking and behavior, Withdrawal syndrome, Sexual dysfunction <20210316>
Other: Diarrhea, nausea, dyspepsia, xerostomia, dizziness, drowsiness, fatigue, insomnia, tremor, headache, paresthesia, anorexia, diaphoresis, decreased libido, delayed ejaculation, ejaculation failure, microscopic colitis<20220318>

Initial dose: 50 mg orally once a day. Maintenance Dose: 50 to 200 mg orally once a day.